Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?

Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16)

You might also be interested in:

Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020
Data Exchange for Drug Rebate Processing and Contract… 08/31/2020
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership 04/10/2020
Stanford Center for Health Education Launches Online Program… 08/11/2020
AHRQ’s Registries User Guide Gets A New Edition 09/24/2020